Contingency Management for Stimulant Use Disorders

Contingency Management Clinical Trial

Official title:

Contingency Management for Stimulant Use Disorders

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05097547
• Other study ID #: HSR210335
• Secondary ID: 17803
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 2021
• Est. completion date: April 2022

Study information

• Verified date: October 2021
• Source: University of Virginia
• Contact: Nassima Ait-Daoud Tiouririne, MD
• Phone: (434)243-0563
• Email: NAT7B[@]hscmail.mcc.virginia.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The invetigators' objective is to implement Medication Assisted Treatment (MAT) and contingency management in patients affected by co-occurring opioid use disorder and stimulant use disorder. Participants will continue to receive standard of care for their opioid use disorder via MAT at our Outpatient Based Opioid Treatment (OBOT) Clinic. Participants' stimulant use disorder will be targeted through contingency management, with twice weekly urine drug screens and monetary prizes in exchange for negative urine drug screens. Through regular clinic visits and the use of incentives, the investigators hope to increase treatment adherence and increase the number of negative urine drug screens in subjects struggling with co-morbid opioid use disorder and stimulant use disorder. The investigators will determine whether or not this treatment is effective in this population, versus conventional treatment (baseline therapy patients were getting through OBOT). The investigators' primary outcome measure will be stimulant abstinence duration during the twelve week study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: April 2022
• Est. primary completion date: April 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 and older

• Patients treated for opioid use disorder in the Outpatient Based Opioid Treatment (OBOT) Clinic and who also struggle with stimulant use disorder but failed conventional treatment (positive urine drug screen for substances other than THC and buprenorphine)

• Ideal candidates will test positive for 3 out of 4 weeks or more prior to starting contingency management

Exclusion Criteria:

• Persons under the age of 18

• Persons not able to attend follow-up clinic visits

• Persons not able to consent

Related Conditions & MeSH terms

• Contingency Management
• Stimulant Use

Intervention

Behavioral:
• Contingency Management
Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Virginia

References & Publications (3)

Ginley MK, Pfund RA, Rash CJ, Zajac K. Long-term efficacy of contingency management treatment based on objective indicators of abstinence from illicit substance use up to 1 year following treatment: A meta-analysis. J Consult Clin Psychol. 2021 Jan;89(1): — View Citation

McPherson SM, Burduli E, Smith CL, Herron J, Oluwoye O, Hirchak K, Orr MF, McDonell MG, Roll JM. A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and — View Citation

Miguel AQ, Madruga CS, Cogo-Moreira H, Yamauchi R, Simões V, da Silva CJ, McPherson S, Roll JM, Laranjeira RR. Contingency management is effective in promoting abstinence and retention in treatment among crack cocaine users in Brazil: A randomized control — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	stimulant abstinence	Duration of stimulant abstinence based on urine drug screens	12 weeks